Articles tagged "Immunosuppression"

2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
¹ELEVATE Study Group, Basel, Switzerland; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…
2016 American Transplant Congress
Impact of Immunosuppressants on Inducing Regulatory T Cells in Human Allo-Immune Responses.
Y. Tanaka, H. Ohdan.
Transplant Surgery, Hiroshima University, Hiroshima, Japan.
A better understanding of cytokine signaling pathways involving transcription factors of the STAT family in T cells responding to allostimulation will improve interpretation of immune-regulatory…
2016 American Transplant Congress
Kidney Transplant Patient Preferences and Trade-Offs for Outcomes After Transplantation.
M. Howell,^1,2 G. Wong,^1,2,3 J. Rose,⁴ A. Tong,^1,2 J. Craig,^1,2 K. Howard.²
¹Centre for Kidney Research, The Childrens Hospital at Westmead, Westmead, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia; ⁴Institute of Choice, University of South Australia, North Sydney, NSW, Australia.
Aim: To evaluate preferences and trade-offs patients may accept to avoid adverse outcomes of long-term immunosuppression. Background: Patient preferences in clinical decisions are increasingly relevant,…
2016 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.
Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.
Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; Kidney Transplant Surgery, Aichi Medical University, Nagoya, Aichi, Japan.
Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…
2016 American Transplant Congress
Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac).
S.-H. Pan, I. Kim, A. Klein, A. Annamalai, T. Todo, N. Nissen.
Liver Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
EVR/rTac has been reported to improve renal function in LT recipients with adequate kidney function (eGFR > 80ml/min); however, this strategy in LT patients with…
2016 American Transplant Congress
Preimplantation and Post-Transplant Serial Biopsies of Standard and Extended Criteria Donor Kidneys: Intragraft Molecular Profiles and Effect of Different Immunosuppressive Protocols.
C. Mazeti,¹ H. Caldas,¹ I. Fernandes-Charpiot,² M. Baptista,² M. Abbud-Filho.^1,2,3
¹Laboratory of Immunology and Experimental Transplantation, Medical School, Sao Jose do Rio Preto, SP, Brazil; ²Department of Medicine/Nephrology, Medical School, Sao Jose do Rio Preto, SP, Brazil; ³Urology and Nephrology Institute, Urology and Nephrology Institute, Sao Jose do Rio Preto, SP, Brazil.
Background: Use of extended criteria donor kidneys (ECD) carries the fear of to transplant of inferior quality and therefore of high discard rate. Clinical tools…
2016 American Transplant Congress
Pneumocystis Pneumonia Following Solid Organ Transplantation, Systematic Review and Meta-Analysis.
S. Hosseini-Moghaddam,^1,2 R. Krishnan.²
¹Medicine, Western University, London, ON, Canada; ²Epidemiology and Biostatistics, Western University, London, ON, Canada.
Background: Different variables have been reported that may increase the risk of pneumocystis pneumonia (PCP) in solid organ transplant patients (SOT).Objectives:To investigate the effect of…
2016 American Transplant Congress
Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.
J. Dickson,¹ W. Vincent III,¹ L. Wu,² J. Thurman,¹ J. Francis,³ M. Nuhn.⁴
¹Pharmacy, Boston Medical Center, Boston, MA; ²Northeastern University, Boston, MA; ³Renal Medicine, Boston Medical Center, Boston, MA; ⁴Transplant Surgery, Boston Medical Center, Boston, MA.
Purpose: Previously, kidney transplant pharmacy services at our institution were limited to medication profile review before and after transplant surgery. Following an OPTN accreditation site…